We are monitoring the impact of COVID-19 on North America Cardiovascular Therapeutic Drugs Market Get in touch with us for detailed analysis Know More
Share on

North America Cardiovascular Therapeutic Drugs Market Research Report – Segmented By Disease, Drug Class & Country (The United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, And Forecast (2022 to 2027)

Published: January, 2022
ID: 1351
Pages: 145

The size of the North American Cardiovascular Therapeutic Drugs Market is estimated to be USD 52.73 billion in 2022 and is poised to reach USD 58.51 billion by 2027 growing at a CAGR of 2.1%. The past several decades have witnessed huge success in the development of effective drug therapies for common cardiovascular disease. These therapies have been widely used with the rising prevalence of cardiovascular diseases resulting in the increased market for cardiovascular therapeutics.

Cardiovascular therapeutic drugs are the prescribed drugs and medicines for the diseases that are related to the structure and function of the heart and blood vessels. Cardiovascular diseases are responsible for majority of the deaths globally and continues to cause health problems. These health problems mainly include heart failure, blood clots, coronary artery disease, high cholesterol and others.

While cardiovascular disorders remain the major cause of morbidity and mortality in the world, the therapeutic drugs market is driven by the increasing aging population, epidemic of general medical problems like obesity & diabetes and growth in the per capita medical spending. However, shrinking target population, rising cost of drug development are the major restraint faced by the market. And, despite the wide prevalence of the cardiovascular diseases, pipelines for drug development products have been stagnant for variety of reasons.

North America cardiovascular therapeutic drug market is categorised on the basis of disease and drug class. On the basis of disease, the market is classified as cardiac arrhythmias, Arteriosclerosis, acute coronary syndrome, Myocardial infarction, Coronary artery disease, Peripheral artery disease, thrombosis, hyperlipidaemia, hypertension, cardiac failure diseases and others. On the basis of drug class the market is categorised as monotherapies and combination drug classes. On the basis of geography of North America, the market is segmented into United States and Canada.

The leading companies in the cardiovascular therapeutic drugs market includes AstraZeneca, Bayer, boehringer ingelheim, Bristol-Myers Squibb (BMS), Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi and Takeda.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease                  

                                5.1.1 Arteriosclerosis     

                                5.1.2 Cardiac arrhythmias            

                                5.1.3 Myocardial infarction         

                                5.1.4 Acute Coronary Syndrome

                                5.1.5 Peripheral artery disease  

                                5.1.6 Coronary artery disease    

                                5.1.7 Hypertension        

                                5.1.8 Hyperlipidaemia   

                                5.1.9 Thrombosis            

                                5.1.10 Cardiac failure diseases  

                                5.1.11 Others   

                5.2 By Drug Class                             

                                5.2.1 Monotherapies     

                                5.2.2 Combination Therapies     

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 United States                            

                6.3 Canada                         

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 AstraZeneca               

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues            

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 Novartis                       

                9.3 Bristol-Myers Squibb                              

                9.4 Pfizer                            

                9.5 Sanofi                           

                9.6 Merck                           

                9.7 Bayer                            

                9.8 Takeda                         

                9.9 Boehringer Ingelheim                            

                9.10 Johnson & Johnson                              

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. North America Cardiovascular Therapeutic Drugs Market, By Region, From 2022 - 2027 (USD Billion)        
  2. North America Cardiovascular Therapeutic Drugs Market, By Disease, From 2022 - 2027 (USD Billion)      
  3. North America Arteriosclerosis Market, By Region, From 2022 - 2027 (USD Billion)            
  4. North America Cardiac arrhythmias Market, By Region, From 2022 - 2027 (USD Billion)   
  5. North America Myocardial infarction Market, By Region, From 2022 - 2027 (USD Billion)
  6. North America Acute Coronary Syndrome Market, By Region, From 2022 - 2027 (USD Billion)      
  7. North America Peripheral artery disease Market, By Region, From 2022 - 2027 (USD Billion)         
  8. North America Coronary artery disease Market, By Region, From 2022 - 2027 (USD Billion)           
  9. North America Hypertension Market, By Region, From 2022 - 2027 (USD Billion)
  10. North America Hyperlipidaemia Market, By Region, From 2022 - 2027 (USD Billion)          
  11. North America Thrombosis Market, By Region, From 2022 - 2027 (USD Billion)   
  12. North America Cardiac failure diseases Market, By Region, From 2022 - 2027 (USD Billion)
  13. North America Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2022 - 2027 (USD Billion) 
  14. North America Monotherapies Market, By Region, From 2022 - 2027 (USD Billion)            
  15. North America Combination Therapies Market, By Region, From 2022 - 2027 (USD Billion)
  16. United States Cardiovascular Therapeutic Drugs Market, By Disease, From 2022 - 2027 (USD Billion)         
  17. United States Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2022 - 2027 (USD Billion)   
  18. Canada Cardiovascular Therapeutic Drugs Market, By Disease, From 2022 - 2027 (USD Billion)     
  19. Canada Cardiovascular Therapeutic Drugs Market, By Drug Class, From 2022 - 2027 (USD Billion)   

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample